SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 52, Issue 4, Pages 457-463
Publisher
Wiley
Online
2011-05-05
DOI
10.1177/0091270011400604
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Turning Glucosuria into a Therapy: Efficacy and Safety with SGLT2 Inhibitors
- (2010) Anupa K. Patel et al. Current Diabetes Reports
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
- (2010) L. Zhang et al. DIABETES OBESITY & METABOLISM
- Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study
- (2010) Elizabeth K. Hussey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
- (2010) Elizabeth K. Hussey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Glucose Control by the Kidney: An Emerging Target in Diabetes
- (2009) Olivera Marsenic AMERICAN JOURNAL OF KIDNEY DISEASES
- Emerging therapies for metabolic diseases—the focus is on diabetes and obesity
- (2009) Thomas E Hughes CURRENT OPINION IN CHEMICAL BIOLOGY
- In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
- (2009) M. Obermeier et al. DRUG METABOLISM AND DISPOSITION
- Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats
- (2009) Yoshikazu Fujimori et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-Ay mice
- (2009) Kenji Katsuno et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Dapagliflozin: an emerging treatment option in type 2 diabetes
- (2009) Mark Kipnes EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes
- (2008) S. A. Jabbour et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models
- (2008) Y. Fujimori et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Recent and emerging anti-diabetes targets
- (2008) Michael L. Mohler et al. MEDICINAL RESEARCH REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started